Optimizing Hypertension Management in Patients with Comorbidities
With Trusted Solutions from Novartis
Select Antihypertensives Based on Comorbidities1
Diabetes & Diabetic Nephropathy
ARBs or ACE inhibitors are preferred for the potential to prevent new-onset diabetes and reduce renal progression.1
Chronic Kidney Disease (CKD)
In patients with microalbuminuria or proteinuria, combining a CCB or diuretic with an (ARB or ACEi) helps reduce albuminuria more effectively.1
Post-Myocardial Infarction (MI)
Beta-blockers and ARB/ACEi are recommended. However, beta-blockers are less protective against stroke and are often discontinued due to side effects.1
Need for Combination Therapy
Most patients require combination treatment—single-pill combinations (SPCs) improve blood pressure control and treatment adherence.1
Ex-EFFeCTs
Significant BP reduction in diabetes HTN patients2
EXCITE
Significant SBP reduction in a range of high CV risk patients: real-world data3
23% reduction of new-onset diabetes
(Diovan vs amlodipine)4
36% reduction of microalbuminuria in patients with type-2-diabetes (Diovan vs amlodipine)5
Diovan®'s efficacy is non-inferior to captopril, with better tolerability profile6
13.2% reduction of morbidities and mortality in HF-patients7,8
Abbreviations:
ACE inhibitors, Angiotensin-Converting Enzyme inhibitors; ARBs, Angiotensin II Receptor Blockers; BP, blood pressure; CCBs, Calcium Channel Blockers; CI, confident interval; CV, Cardiovascular; ESC, European Society of Cardiology; EXCITE, Experience of amlodipine and valsartan in hypertension; EX-EFFeCTS, Exforge - Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension; HCT, Hydrochlorothiazide; HF, heart failure; HR, hazard ratio; HTN, hypertension; MI, Myocardial Infarction; SBP, Systolic Blood Pressure; UAER, urinary albumin excretion rate.
References:
1. McEvoy JW et al. Eur Heart J. 2024;45(38):3912–4018. 2. Destro M et al. J Am Soc Hypertens. 2008;2(4):294–302 3. Assaad-Khalil SH et al. Vasc Health Risk Manag 2015; 11: 71-78. 4. Julius S et al. Lancet 2004;363(9426): 2022-2031. 5. Viberti G et al. Circulation 2002;106(6): 672-678. 6. Pfeffer MA et al; for the Valsartan in Acute Myocardial Infarction Trial Investigators. N Engl J Med 2003; 349(20): 1893-1906. 7. Cohn JN; for the Valsartan Heart Failure Trial Investigators. N Engl J Med 2001; 345(23): 1667-1675. 8. Maggioni AP et al; on behalf of the Val-HeFT Investigators. J Am Coll Cardiol 2002; 40(8): 1414-1421.
20 Pasir Panjang Road #10-25/28 Mapletree Business City (West Tower) Singapore 117439
Phone: +65 6722 6010
This content is not for local distribution. This should be modified to accommodate local guidance before local distribution.
FOR HEALTHCARE PROFESSIONALS ONLY
APPROVAL CODE
